DiscoverThe Integration Session
The Integration Session
Claim Ownership

The Integration Session

Author: The Centre for Psychedelics Health and Research

Subscribed: 2Played: 12
Share

Description

The Integration Session is for staying up-to-date on all things psychedelic science, with the experts themselves. This podcast takes an integrative approach—sharing research findings, their clinical relevance, and reaching towards solutions to key challenges in the field today. Hosted by Dr. Elena Koning, this show is where scientists connect to discuss anything from mechanisms and study design to ethics and policy. If you’re a scientist, trainee, or simply someone who wants to dig deeper, tune in for engaging discussions about psychedelics and their promising future in healthcare and beyond.
40 Episodes
Reverse
As psychedelic treatments move closer to broader clinical use, treatment protocols are being trimmed down in the name of cost and scale. Integration sessions in particular are being reduced, though they importantly give patients space to process the psychedelic experience and turn what they learned into lasting therapeutic change.When these sessions are cut short, how might that work fall to partners, family members, and friends instead? And how can we make sure patients are adequately supported?In this episode, we are joined by two co-authors of a recent Perspective in the Canadian Journal of Psychiatry, “As Psychedelic Treatments Get Leaner, Patients’ Social Environments Deserve Attention,” which takes up these questions.Ian Roullier is the co-founder of the Psychedelic Participant Advocacy Network (PsyPAN). Ian’s participation in clinical trials run by Imperial College (2015) and King’s College/Compass Pathways (2019) inspired his dedication to helping bring these treatments safely to all who may benefit from them. His advocacy work has included giving public talks alongside Dr. Rosalind Watts (Imperial College/ACER Integration), speaking at international conferences such as ICPR, Borealis and Breaking Convention, addressing policy makers at the European Parliament and at the European Medicines Agency and having his journey featured by Oprah, the BBC and in Michael Pollan's bestseller 'How To Change Your Mind'. Ian is also an ACER Integration sharing circle facilitator and was part of the King's College PsiDeR trial steering committee. PsyPAN works with organisations to ensure participant wellbeing is placed at the heart of their trials and treatments, feeds the participant voice into scientific research to help improve psychedelic safeguarding and fosters community and connection for people who have received psychedelic-assisted therapy.Dr Edward Jacobs is a postdoctoral fellow in psychedelic science at Johns Hopkins, and the associate director of HOPE, the Hub at Oxford for Psychedelic Ethics. Following his PhD in the ethics of psychedelic therapies, his current research spans the influence of worldview on psychedelic experiences, stakeholder perceptions of psychedelic science, and the ethics of AI in psychedelic care. Through HOPE, he has contributed to US congressional and federal inquiries on the rollout of clinical psychedelics. Learn more at https://psychedelicethics.com If you’re listening to this podcast in November 2026, you’re invited to contribute to the Psychedelic Stakeholder Survey. Go to https://psychedelicsurvey2026.com Jacobs, E., Roullier, I., Watts, R., & Wells, H. (2026). As Psychedelic Treatments Get Leaner, Patients' Social Environments Deserve Attention. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 7067437261479491. Advance online publication. https://doi.org/10.1177/07067437261479491
Alberta is Canada’s first province to regulate psychedelic treatments, but when this change took effect in early 2023, it classified ketamine in the same category as psilocybin, MDMA, and LSD, under one “psychedelic-assisted psychotherapy” framework. So, what are the risks of lumping different psychedelic treatment models together? And what is the solution moving forward? In this episode, Dr. Jennifer Swainson, a psychiatrist and Clinical Professor at the University of Alberta, explains why terminology matters in psychedelic science, how we should be defining ketamine treatments, where the role of psychotherapy fits in, and key considerations for patients, clinicians, regulators, and researchers moving forward. More About Dr. Swainson: Jennifer N. Swainson, MD, FRCPC, DABOM is a Clinical Professor in the Department of Psychiatry at the University of Alberta, Diplomate of the American Board of Obesity Medicine, and a psychiatrist at the Misericordia Hospital in Edmonton, Canada. Dr. Swainson specializes in the management of difficult to treat mood disorders and their common comorbid conditions. She is a nationally recognized expert in the use of ketamine for depression and a leader in the development and update of Canadian guideline statements on this topic. Dr. Swainson is a clinical researcher with numerous publications related to ketamine for depression, with a focus on nomenclature for treatment models with ketamine and psychotherapy, and the use of oral or sublingual ketamine at home in order to improve patient access, while balancing concerns for safety. Dr. Swainson’s expertise has informed development of Alberta’s provincial Intravenous ketamine protocol, and she has provided consultation to the College of Physicians and Surgeons of Alberta regarding accreditation standards for safe prescribing of ketamine, both as pharmacotherapy and in psychotherapy-based treatment models.
What are the biggest gaps between psychedelic trials and what actually happens in the dosing room? And how might an Ayahuasca-inspired drug formulation affect shame and self-referential thinking? In this episode, we are joined by Dr. Helena Aicher, a research associate at the University of Zurich and Basel, where she is involved in clinical trials investigating psychedelic interventions. Alongside her research, she works as a psychotherapist within Switzerland’s limited medical use pathway and trains clinicians preparing to work in this field. In this conversation, we discuss her recent work on a combined DMT-harmine formulation inspired by Ayahuasca, including its effects on self-referential emotions like shame and embarrassment. Helena also shares her opinions on clinical aspects of psychedelic therapy, including the role of touch, the risks and benefits of group-based protocols, and gaps in facilitator training. More About Dr. Helena Aicher: Helena is a research associate at the Universities of Zurich and Basel, where she is involved in clinical trials investigating psychedelics. Alongside her research role, she works as a psychotherapist including the limited medical use of psychedelics in Switzerland, primarily in group settings. Bridging scientific research and frontline practice, she contributes to the development and safe implementation of psychedelic-assisted therapies. Helena is also active as a trainer in therapist training programs and serves as an advisor to several institutions.
Therapeutic touch is often used in psychedelic therapy, but what ethical guidelines and boundaries should researchers and therapists follow? What can we learn from patient perspectives about consent, and where to draw the line?In this episode, Dr. Rachel Ham joins us from Monash University in Melbourne, Australia to discuss two companion studies from her research group: one capturing experiences of therapeutic touch from participants in a psilocybin trial, and the other capturing how researchers and therapists think through consent, boundaries, and the discomfort of getting it wrong. We discuss the gap between what participants expect touch to feel like and what it turns out to mean to them, the ethical tension around withholding contact from someone in genuine distress, and what a truly individualized consent process for psychedelic medicine might look like.
Psychedelics are often described as capable of “rewiring the brain,” but this leaves out a more complex and elegant series of mechanisms beneath the cortex. This episode goes a layer deeper to explore specific brain regions and receptors that are less often talked about in psychedelic science, despite their critical role in psychedelic drug action. Dr. Tanner Anderson, a postdoctoral neuroscientist at Yale School of Medicine, takes us on a tour through his research career so far, including his research on the claustrum (the brain's so-called "conductor" of consciousness) where he showed that the psychedelic DOI can reverse synaptic plasticity at claustrum-cortical synapses and the importance of serotonin receptors beyond 5-HT2A. We also discuss his work linking cocaine, claustrum function, and cognitive flexibility, and his current research at Yale on how MDMA affects fear circuits implicated in PTSD.Finally, Tanner helps us answer broader questions: Are psilocybin, DOI, MDMA, and ketamine converging on some shared mechanism of "reopening" plasticity in the brain, or are they doing genuinely different things in different circuits? What would it take for the field to move from compelling mechanistic stories to something clinicians can actually rely on?More About Tanner: Tanner L. Anderson, PhD, is a postdoctoral neuroscientist in the Department of Psychiatry at Yale School of Medicine. His research examines how psychedelics and entactogens alter neuronal activity and synaptic plasticity in brain circuits involved in cognition, anxiety, depression, and substance use disorders. He combines slice patch-clamp electrophysiology, Neuropixels recordings, optogenetics, viral circuit tracing, and behavioral neuroscience to study how these compounds produce both immediate and lasting changes in the brain. Tanner earned his PhD in Neuroscience from the University of Kentucky, where his research focused on psychedelic modulation of neuronal signaling and plasticity in the claustrum. Tanner is a recipient of an NIH NRSA F31 Fellowship from the National Institute on Drug Abuse and is interested in the intersection of psychedelic science, drug policy, and the development of more effective treatments for psychiatric diseases.Tanner’s Socials: linkedin.com/in/tanner-anderson-uky https://x.com/EphysTanner @tanner-anderson.bsky.social
loading
Comments